Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment
© 2024 The Authors..
The non-selective cytotoxicity of toxins limits the clinical relevance of the toxins. In recent years, toxins have been widely used as warheads for antibody‒drug conjugates (ADCs) due to their efficient killing activity against various cancer cells. Although ADCs confer certain targeting properties to the toxins, low drug loading capacity, possible immunogenicity, and other drawbacks also limit the potential application of ADCs. Recently, non-ADC delivery strategies for toxins have been extensively investigated. To further understand the application of toxins in anti-tumor, this paper provided an overview of prodrugs, nanodrug delivery systems, and biomimetic drug delivery systems. In addition, toxins and their combination strategies with other therapies were discussed. Finally, the prospect and challenge of toxins in cancer treatment were also summarized.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Acta pharmaceutica Sinica. B - 14(2024), 4 vom: 13. Apr., Seite 1542-1559 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Xiaolan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomimetic drug delivery systems |
|---|
| Anmerkungen: |
Date Revised 05.04.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.apsb.2023.11.029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370615239 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370615239 | ||
| 003 | DE-627 | ||
| 005 | 20240405234312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240405s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.apsb.2023.11.029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM370615239 | ||
| 035 | |a (NLM)38572098 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Xiaolan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a The non-selective cytotoxicity of toxins limits the clinical relevance of the toxins. In recent years, toxins have been widely used as warheads for antibody‒drug conjugates (ADCs) due to their efficient killing activity against various cancer cells. Although ADCs confer certain targeting properties to the toxins, low drug loading capacity, possible immunogenicity, and other drawbacks also limit the potential application of ADCs. Recently, non-ADC delivery strategies for toxins have been extensively investigated. To further understand the application of toxins in anti-tumor, this paper provided an overview of prodrugs, nanodrug delivery systems, and biomimetic drug delivery systems. In addition, toxins and their combination strategies with other therapies were discussed. Finally, the prospect and challenge of toxins in cancer treatment were also summarized | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biomimetic drug delivery systems | |
| 650 | 4 | |a Cancer treatment | |
| 650 | 4 | |a Combination strategies | |
| 650 | 4 | |a Delivery strategies | |
| 650 | 4 | |a Nano drug delivery systems | |
| 650 | 4 | |a Non-antibody‒drug conjugates | |
| 650 | 4 | |a Prodrugs | |
| 650 | 4 | |a Toxins | |
| 700 | 1 | |a Zhang, Jiaming |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Rong, Yukang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanfang |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Chenxia |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Ran, Xiaohua |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yingli |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Tianhong |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Qikun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmaceutica Sinica. B |d 2012 |g 14(2024), 4 vom: 13. Apr., Seite 1542-1559 |w (DE-627)NLM227628217 |x 2211-3835 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:4 |g day:13 |g month:04 |g pages:1542-1559 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.apsb.2023.11.029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 4 |b 13 |c 04 |h 1542-1559 | ||